Jeff Settleman News Today

Working to Outdo Cancer: A Multi-Modality Approach to Accelerating the Next Generation of Cancer Breakthroughs Friday, April 05, 2024 - 09:30am ...

NEW YORK CITY (dpa-AFX) - ORIC Pharmaceuticals Inc. (ORIC) said that it has reached a clinical development collaboration with Pfizer for a potential phase 2 study of ORIC-533 in multiple myeloma.ORIC

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Manuel Esteban / Shutterstock.com ORIC Pharmaceuticals (NASDAQ:ORIC)...

Though Gilead Sciences leads the group of companies developing immunotherapies that target the cancer protein CD47, Pfizer contends that molecules it is getting through the Trillium Therapeutics acquisition have safety and efficacy advantages that could make them the best in this emerging drug class.

Pfizer pours $25m into Vedantas Phase II IBD study The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate. PureTech Health, a clinical-stage biotherapeutics firm, has announced its Vedanta Biosciences founded entity has landed a $25m (20.6 EUR) investment as part of the Pfizer Breakthrough Growth Initiative (PGBI). Vedanta plans to use the money to fund its Phase II st...

Pfizer is investing US$25m in a US developer of live biotherapeutics, Vedanta Biosciences; that project is one of four investments, totaling US$120m, made by Pfizer in the second half of 2020 under its breakthrough growth program focused on clinical stage biotech companies of potential future strategic interest to the pharma giant.

These updates are republished press releases and communications from members of the Science|Business Network Pfizer invests $120M in four biotechnological innovation companies Pfizer Inc. today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfiz...

First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology,...